100 related articles for article (PubMed ID: 11084461)
41. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
42. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
43. [Cytoreductive surgery in the management of stage IV epithelial ovarian cancer].
Zang R; Zhang Z; Chen J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):197-9. PubMed ID: 11776157
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
45. A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
Obermair A; Fuller A; Lopez-Varela E; van Gorp T; Vergote I; Eaton L; Fowler J; Quinn M; Hammond I; Marsden D; Proietto A; Carter J; Davy M; Tripcony L; Abu-Rustum N
Gynecol Oncol; 2007 Mar; 104(3):607-11. PubMed ID: 17092548
[TBL] [Abstract][Full Text] [Related]
46. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
47. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.
Aletti GD; Dowdy SC; Podratz KC; Cliby WA
Gynecol Oncol; 2006 Feb; 100(2):283-7. PubMed ID: 16182350
[TBL] [Abstract][Full Text] [Related]
48. [Analysis of risk factors for epithelial ovarian cancer recurrence].
Liu S; Liu JH; Huang H; Peng XP; Wang YM
Ai Zheng; 2003 Nov; 22(11):1197-200. PubMed ID: 14613652
[TBL] [Abstract][Full Text] [Related]
49. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
50. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
51. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R
Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
[TBL] [Abstract][Full Text] [Related]
52. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma.
Farley JH; Hickey KW; Carlson JW; Rose GS; Kost ER; Harrison TA
Cancer; 2003 May; 97(9):2196-202. PubMed ID: 12712471
[TBL] [Abstract][Full Text] [Related]
53. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
54. Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma.
Chen KY; Chang CH; Yu CJ; Kuo SH; Yang PC
Cancer; 2005 Jun; 103(12):2566-74. PubMed ID: 15852359
[TBL] [Abstract][Full Text] [Related]
55. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.
Engelen MJ; Kos HE; Willemse PH; Aalders JG; de Vries EG; Schaapveld M; Otter R; van der Zee AG
Cancer; 2006 Feb; 106(3):589-98. PubMed ID: 16369985
[TBL] [Abstract][Full Text] [Related]
56. [Prognostic study of ovarian clear cell carcinoma].
Takahashi S; Murae M; Tahira K; Yamamoto K; Ochiai K; Kimura E; Morimoto O; Yasuda M; Terashima Y; Dozono H
Nihon Gan Chiryo Gakkai Shi; 1989 Jun; 24(6):1238-42. PubMed ID: 2794647
[TBL] [Abstract][Full Text] [Related]
57. Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer.
Barber HR; Sommers SC; Synder R; Kwon TH
Am J Obstet Gynecol; 1975 Mar; 121(6):795-807. PubMed ID: 1092171
[TBL] [Abstract][Full Text] [Related]
58. [Factors that influence the late treatment results in ovarian cancer].
Petrov AM
Vopr Onkol; 1980; 26(5):32-6. PubMed ID: 7385713
[TBL] [Abstract][Full Text] [Related]
59. The grading of lymphovascular space invasion in epithelial ovarian carcinoma.
Qian X; Xi X; Jin Y
Int J Gynecol Cancer; 2010 Jul; 20(5):895-9. PubMed ID: 20606540
[TBL] [Abstract][Full Text] [Related]
60. Ovarian adenocarcinoma: prognostic evaluation after first laparotomy.
Villet R
Bull Cancer; 1993 Feb; 80(2):142-5. PubMed ID: 8173165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
